Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Webcasts|October 11, 2022

Best Practices in HCP Assay Development and Integration of Advanced Orthogonal Methods

Tuesday, October 11, 2022 at 11 AM EDT Learn about best practices in Host Cell Protein (HCP) assay development and qualification. Improve your understanding of the advanced orthogonal methods used to fully characterize HCPs in your process

Register Free: https://www.biopharminternational.com/bp/integration

Event Overview:

A well-developed and broadly reactive host cell protein (HCP) Enzyme-Linked Immunosorbent Assay (ELISA) is a sensitive and specific method used during the purification process of biologics to ensure removal of HCPs and to demonstrate process consistency and final drug substance purity. Regulatory guidelines require that sponsors use orthogonal methods for demonstrating antibody coverage to individual HCPs and provide a comprehensive assay qualification package to ensure the HCP ELISA is fit for purpose.
In this webinar, a Cygnus Technologies expert will discuss:

  • Types of HCP immunoassays
  • Best practices in HCP immunoassay development
  • Common mistakes and misconceptions that can misguide assay developers
  • Advanced orthogonal methods of immunoaffinity chromatography and mass spectrometry to fully qualify HCP ELISA and characterize individual HCPs in in-process and drug substance samples


Key Learning Objectives:

  • Understand best practices in HCP immunoassay development
  • Learn about advanced orthogonal methods for HCP ELISA qualification
  • Learn how orthogonal method integration enables data-driven decisions on whether a process-specific assay is necessary and/or superior to a well-developed generic or platform method

Who Should Attend:

  • Analytical scientists supporting biologics process development, manufacturing, and quality control
  • Process development scientists
  • Chemistry, manufacturing, and controls (CMC) departments
  • Regulatory consultants
  • Regulatory scientists

Speaker

John Locklear
Technical Services Manager
Cygnus Technologies

As a technical services manager, John Locklear leads technical support for Cygnus Technologies customers worldwide. Since joining Cygnus Technologies’ R&D department in 2011, Locklear developed many generic and custom HCP ELISA assays for several mammalian, yeast, and bacterial cell culture platforms as well as several host cell DNA assays. Locklear received a B.S. in biotechnology from the University of North Carolina at Pembroke.

Register Free: https://www.biopharminternational.com/bp/integration


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.